Viking Therapeutics Today VKTX Viking Therapeutics $64.45 +1.51 (+2.40%) 52-Week Range $8.28 ▼ $99.41 Price Target $108.60 Add to Watchlist Viking Therapeutics Inc. NASDAQ: VKTX, a clinical-stage biotechnology company with a market cap approaching $7 billion, is turning heads in 2024. Year to date, the stock has surged an impressive 238%, and its rise over the past 12 months has been even more dramatic, with shares climbing 326%. For a mid-cap biotech, these kinds of gains significantly outpace both the bro ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $67.10, demonstrating a +0.55% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.13% for the day. On the other hand, the Dow registered a gain of 0.55%, and the technology-centric Nasdaq decreased by 0.52%. Shares of the company witnessed a gain of 17.67% over the previous month, beating the performance of the Medical sector with its gain of 3.34% and the S&P 500's gain of 3.67%. The ...

The company is looking especially good after some bad news coming from a rival. For the second day in a row, a pundit's take on Viking Therapeutics (VKTX 3.25%) helped push the biotech's share price higher. It was this rather than inherent news from the company that added more than 3% to said price, a gain that handily beat the S&P 500 index's 0.8% increase. Thumbs-up from bullish pundit The latest analyst to weigh in on Viking's prospects was Morgan Stanley's Michael Ulz, who early Thursday morning publish ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Viking Therapeutics, Inc. (VKTX) . Viking Therapeutics currently ...

The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug. Viking Therapeutics (VKTX 11.31%) stormed the stock market on Wednesday. Shares of the up-and-coming biotech rose by more than 11% not on any proprietary news from the company, but on an analyst's initiation of coverage. That performance was more than enough to top the trajectory of the bellwether S&P 500 index, which rose by slightly over 1% on the day. 32% upside potential, analyst b ...

Key Takeaways Shares of Viking Therapeutics surged Wednesday after J.P. Morgan analysts initiated coverage of the drugmaker at "overweight" and shared an optimistic view. Viking is developing weight-loss drugs that have boosted its stock after positive trial results since the start of this year, and analysts say it might happen again. In the long term, analysts predict that Viking's anticipated oral weight-loss drug could claim about 10% of the market in the years following its projected 2030 release. Vikin ...

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc VKTX with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65. At the core of this bullish outlook is Viking's obesity drug candidate, oral-2735, which could be a significant player in the rapidly expanding GLP-1 market. Oral-2735 Could Be A Game Changer JPMorgan highlights oral-2735's potential as a highly competitive treatment in the GLP-1 market, par ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $54.78, denoting a +1.2% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 1.16%. Elsewhere, the Dow gained 1.2%, while the tech-heavy Nasdaq added 1.16%. The company's stock has dropped by 5.3% in the past month, falling short of the Medical sector's gain of 4.5% and the S&P 500's gain of 3.48%. The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The co ...

The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock. Wall Street investment banks keep pounding the table on Viking Therapeutics (VKTX -2.27%) and its weight loss drug candidate. Predictions vary, but the average analyst who follows the stock thinks it can rise 98% from recent prices. Investment bank analysts aren't the only folks on Wall Street who think the clinical-stage biopharma has a bright future. In the second quarter, billionaire mone ...

Nvidia is heading for a 118% gain this year. Nvidia (NVDA -1.66%) is a tough one to beat when it comes to share-price performance. The technology giant has seen its shares soar 2,500% over the past five years, and this year, it's heading for a 118% increase. There's a good reason for this incredible run. Nvidia dominates one of today's biggest growth areas -- the artificial intelligence (AI) chip market -- holding an 80% share. As a result, Nvidia's earnings have been climbing in the triple digits to new re ...